Researchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells throughout the body.
The “in situ vaccination” worked so well in patients with advanced-stage lymphoma that it is also undergoing trials in breast and head and neck cancer patients, according to a study published in Nature Medicine in April.
The treatment consists of administering a series of immune stimulants directly into one tumor site. The first stimulant recruits important immune cells called dendritic cells that act like generals of the immune army. The second stimulant activatesthe dendritic cells, which then instruct T cells, the immune system’s soldiers, to kill cancer cells and spare non-cancer cells. This immune army learns to recognize features of the tumor cells so it can seek them out and destroy them throughout the body, essentially turning the tumor into a cancer vaccine factory.
“The in situ vaccine approach has broad implications for multiple types of cancer,” said lead author Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “This method could also increase the success of other immunotherapies such as checkpoint blockade.”
After testing the lymphoma vaccine in the lab, it was tested in 11 patients in a clinical trial. Some patients had full remission from months to years. In lab tests in mice, the vaccine drastically increased the success of checkpoint blockade immunotherapy, the type of immunotherapy responsible for the complete remission of former President Jimmy Carter’s cancer and the focus of the 2018 Nobel Prize in Medicine.
A clinical trial for lymphoma, breast, and head and neck cancer patients opened in March to test the vaccine with checkpoint blockade drugs. Because the combined immune therapy was at least three times more powerful than either checkpoint blockade or the vaccine by themselves, researchers are extremely optimistic about how effective this may be in patients in this new trial. The in situ vaccine is also being tested in the lab in liver and ovarian cancer.
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Living with brain cancer has prepared me for coronaviruson March 22, 2020 at 7:07 am
With my illness, I’ve already have had to self-isolate several times. I’ve also learned a valuable lesson that others can now follow: Ask for help.
- Health Kick Podcast: Understanding immunotherapy, why the drug market dried up and Immutep’s profitable potentialon March 22, 2020 at 2:40 am
Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment ... Read More The post Health Kick Podcast: Understanding ...
- Gut bacteria may boost cancer therapy by colonizing tumorson March 20, 2020 at 4:53 am
The authors of the new study, which features in the Journal of Experimental Medicine, note that certain bacteria have also demonstrated the ability to improve the efficacy of cancer immunotherapy by ...
- Immunotherapy treatment shows promise for some patients with advanced rare cancerson March 19, 2020 at 9:19 pm
A study conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated acceptable toxicity and anti-tumor activity in patients with four types of advanced, hard-to-treat ...
- Chi Lin, MD, PhD, on Immunotherapy and Chemoradiation in Pancreatic Canceron March 19, 2020 at 1:24 pm
Immunotherapy can be said to have revolutionized the treatment landscape of various malignancies, but less so in pancreatic cancer. The majority of the initial clinical trials in pancreatic cancer ...
- Cancer Immunotherapy Market 2020 Global Analysis, Opportunities and Forecast to 2025on March 19, 2020 at 3:13 am
New York, March 19, 2020:The cancer immunotherapy marketis expected to grow more than US$ 173 Billion by 2024; Growing at a CAGR of more than 14% in the given forecast period. The report covers ...
- Cancer Immunotherapy Market Size is Projected to Reach US$ 115.4 Billion by 2026on March 19, 2020 at 1:11 am
Cancer Immunotherapy Market (by product type:Monoclonal Antibodies)(by product type:Vaccines)(by product type:Checkpoint Inhibitors)(by product type:Cell Therapies)(by product ...
- How CAR-T Immunotherapy Improves Quality of Life After Cancer Treatmenton March 18, 2020 at 4:03 pm
Share on Pinterest Experts say CAR-T immunotherapy strengthens the body’s immune response to fight cancer, a process that can improve a person’s quality of life after treatment. Getty Images ...
- A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal canceron March 18, 2020 at 11:44 am
These authors contributed equally to this work. See allHide authors and affiliations Neoantigen vaccines have been enthusiastically pursued for personalized cancer immunotherapy while vast majority of ...
- Agenus Reveals Improved Cancer Immunotherapy Therapy Resultson March 16, 2020 at 7:08 pm
That said, partial responses are good in this type of cancer. On the whole, if the Agenus patients continue to show improvement ... Source: Slide 85, Agenus February 2020 presentation Currently, there ...
via Bing News